Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 16/20 | 1.00 |
| ▸ | TLR1 | Q15399 | 16/20 | 1.00 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17243299 | 0.90 | TLR2 (0.83) | TLR2TLR1MAPTRAB9ANPC1 | |
| SCHEMBL16692239 | 0.90 | TLR2 (1.00) | TLR2TLR1MAPTRAB9ANPC1 | |
| SCHEMBL17242564 | 0.88 | TLR2 (0.87) | TLR2TLR1MAPTRAB9ANPC1 | |
| SCHEMBL17243259 | 0.87 | TLR2 (0.89) | TLR2TLR1MAPTRAB9ANPC1 | |
| SCHEMBL21462062 | 0.87 | TLR2 (1.00) | TLR2TLR1ALKBH5MAPT | |
| SCHEMBL30279803 | 0.87 | TLR2 (1.00) | TLR2TLR1ALKBH5MAPT | |
| SCHEMBL17242583 | 0.86 | TLR2 (0.87) | TLR2TLR1ALKBH5MAPTRAB9A | |
| SCHEMBL17242638 | 0.85 | TLR2 (0.86) | TLR2TLR1ALKBH5MAPT | |
| SCHEMBL17242755 | 0.85 | TLR2 (0.73) | TLR2TLR1 | |
| SCHEMBL17242494 | 0.84 | TLR2 (0.83) | TLR2TLR1MAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743119-A1 | FORMULATED AND/OR CO-FORMULATED LIPOSOME COMPOSITIONS CONTAINING TGFB ANTAGONIST PRODRUGS USEFUL IN THE TREATMENT OF CANCER AND METHODS THEREOF | Nammi Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| US-20260014092-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR USE FOR VACCINES AND FOR IMMUNOMODULATION | AGS THERAPEUTICS SAS (FR) | 2026-01-15 | — | — | US | claimed |
| WO-2025136749-A1 | THYMIC EPITHELIAL CELLS AND METHODS OF PRODUCING AND USING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-06-26 | — | — | WO | claimed |
| WO-2025058654-A1 | FORMULATED AND/OR CO-FORMULATED LIPOSOME COMPOSITIONS CONTAINING TGFB ANTAGONIST PRODRUGS USEFUL IN THE TREATMENT OF CANCER AND METHODS THEREOF | NAMMI THERAPEUTICS, INC. (US) | 2025-03-20 | — | — | WO | claimed |
| WO-2025047993-A1 | ANTI-DOPPEL ANTIBODY DRUG CONJUGATES | PHAROSGEN CO., LTD. (KR) | 2025-03-06 | — | — | WO | claimed |
| US-20250032620-A1 | Formulated and/or Co-Formulated Nanocarrier Compositions Containing TFGß Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof | NAMMI THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20240366772-A1 | Formulated and/or Co-Formulated Liposome Compositions Containing PD-1 Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof | NAMMI THERAPEUTICS, INC. | 2024-11-07 | — | — | US | claimed |
| CN-118717755-A | Use of NF- κB agonist CU-T12-9 | 中国人民解放军东部战区总医院 | 2024-10-01 | — | — | CN | claimed |
| WO-2024194423-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR USE FOR VACCINES AND FOR IMMUNOMODULATION | AGS THERAPEUTICS SAS (FR) | 2024-09-26 | — | — | WO | claimed |
| US-12059470-B2 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. (US) | 2024-08-13 | — | — | US | claimed |
| US-20240082407-A1 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. | 2024-03-14 | — | — | US | claimed |
| US-20240050575-A1 | Formulated and/or co-formulated liposome compositions containg TGFb antagonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. | 2024-02-15 | — | — | US | claimed |
| US-11833209-B2 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | claimed |
| US-11801304-B2 | Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | claimed |
| CN-116507341-A | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs for treating cancer and methods thereof | 纳米医疗有限公司 | 2023-07-28 | — | — | CN | claimed |
| EP-4211144-A1 | FORMULATED AND/OR CO-FORMULATED LIPOSOME COMPOSITIONS CONTAINING PD-1 ANTAGONIST PRODRUGS USEFUL IN THE TREATMENT OF CANCER AND METHODS THEREOF | Nammi Therapeutics, Inc. (US) | 2023-07-19 | — | — | EP | claimed |
| EP-4096716-A1 | FORMULATED AND/OR CO-FORMULATED LIPOSOME COMPOSITIONS CONTAINING TGFB ANTAGONIST PRODRUGS USEFUL IN THE TREATMENT OF CANCER AND METHODS THEREOF | Nammi Therapeutics, Inc. (US) | 2022-12-07 | — | — | EP | claimed |
| CN-115243724-A | Formulated and/or co-formulated liposomal compositions containing TFG beta antagonist prodrugs and methods thereof useful for treating cancer | 纳米医疗有限公司 | 2022-10-25 | — | — | CN | claimed |
| WO-2022055542-A1 | FORMULATED AND/OR CO-FORMULATED LIPOSOME COMPOSITIONS CONTAINING PD-1 ANTAGONIST PRODRUGS USEFUL IN THE TREATMENT OF CANCER AND METHODS THEREOF | NAMMI THERAPEUTICS, INC. (US) | 2022-03-17 | — | — | WO | claimed |
| US-20220080051-A1 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. | 2022-03-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240082407-A1 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | CD274, PDCD1LG2, PDCD1 | TLR2 1066/4885TLR1 289/4885ALKBH5 4124/4885 |
| US-11833209-B2 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | CD274, PDCD1LG2, PDCD1 | TLR2 1066/4885TLR1 289/4885ALKBH5 4124/4885 |
| US-20250032620-A1 | Formulated and/or Co-Formulated Nanocarrier Compositions Containing TFGß Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof | ALK, PLIN5, TBC1D5 | TLR2 1051/4885TLR1 371/4885ALKBH5 46/4885 |
| US-20240366772-A1 | Formulated and/or Co-Formulated Liposome Compositions Containing PD-1 Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof | CD274, PDCD1LG2, PDCD1 | TLR2 1066/4885TLR1 289/4885ALKBH5 4124/4885 |
| US-20240050575-A1 | Formulated and/or co-formulated liposome compositions containg TGFb antagonist prodrugs useful in the treatment of cancer and methods thereof | TGFBR1, TGFB1, TGFBR2 | TLR2 1082/4885TLR1 739/4885ALKBH5 44/4885 |
| US-20220080051-A1 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | CD274, PDCD1LG2, PDCD1 | TLR2 1066/4885TLR1 289/4885ALKBH5 4124/4885 |
| US-12059470-B2 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | CD274, PDCD1LG2, PDCD1 | TLR2 1066/4885TLR1 289/4885ALKBH5 4124/4885 |
| US-20260014092-A1 | EXTRACELLULAR VESICLES FROM MICROALGAE, THEIR USE FOR VACCINES AND FOR IMMUNOMODULATION | TLR9, TLR1, TLR2 | TLR2 3/4885TLR1 2/4885ALKBH5 4272/4885 |
| US-11801304-B2 | Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof | TBC1D5, FABP5, PLIN5 | TLR2 1594/4885TLR1 850/4885ALKBH5 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.